Turning Point Therapeutics Inc (NASDAQ:TPTX)

Stock Price: $76.01
+0 (0%)
Updated Aug 16, 2022 04:00 AM GMT+0000
Featured app
Invest now
<p>79% of retail CFD accounts lose money</p>
Market Cap 3.81B
Revenue 0
Gross Profit 0
Shares Out 50.07M
EPS (ttm)
PE Ratio 0.0000
Forward PE 0.0000
Dividend Rate (ttm) 0.0000
Dividend Yield 0.0000
Trading Day Aug 16
Last Price $76.01
Previous Close $76.01
Change ($) 0
Change (%) 0%
Day's Open 76.01
Day's Range 75.98 - 76.01
Day's Volume 0
52 Week Range 0 - 76.01

About Turning Point Therapeutics Inc

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors.

Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company's pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor currently pending IND submission.

Turning Point's next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.


Quick info

Pharmaceutical Preparation Manufacturing
Ticker Symbol
Reporting Currency